A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump

The HeartMate 3 Left Ventricular Assist System has demonstrated absence of confirmed de-novo pump thrombosis and reduction in stroke. However, bleeding related adverse events persist under standard anticoagulation targeting a INR range of 2.0-3.0. In an initial experience we demonstrated safety of transition to low intensity anticoagulation (INR target 1.5-1.9, n=15, follow up of at least 6 months). Whether complete cessation of anticoagulation maintains “thromboresistance” in the HeartMate 3 pump remains unknown.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: I. Netuka, P. Ivak, Z. Tucanova, S. Gregor, O. Szarszoi, J. Rimsans, J. Connors, D. Crandall, P. Sood, M. Mehra Tags: 254 Source Type: research